Skip Nav Destination
Issues
15 July 2009
-
Cover Image
Cover Image
Urokinase plasminogen activator receptor—targeted magnetic iron oxide nanoparticles are produced by conjugating a near-IR dye—labeled recombinant peptide containing the amino-terminal fragment of urokinase plasminogen activator. Urokinase plasminogen activator receptor is upregulated in breast cancer and tumor stromal cells. Systemic delivery of the receptor targeted nanoparticles leads to the accumulation of the nanoparticle imaging probes in the primary and metastatic tumor lesions in a mouse mammary tumor model and allows for the detection of breast cancer by MRI and optical imaging. For further details, please see Yang and colleagues on page 4722 in this issue. - PDF Icon PDF LinkTable of Contents
ISSN 1078-0432
EISSN 1557-3265
CCR Translations
Molecular Pathways
Perspective
Human Cancer Biology
Down-regulation of Epidermal Growth Factor Receptor by Selective Expansion of a 5′-End Regulatory Dinucleotide Repeat in Colon Cancer with Microsatellite Instability
Svetlana Baranovskaya; Yolanda Martin; Sergio Alonso; Ksenia L. Pisarchuk; Mario Falchetti; Yuichi Dai; Sophia Khaldoyanidi; Stan Krajewski; Inna Novikova; Yuri S. Sidorenko; Manuel Perucho; Sergei R. Malkhosyan
Activation of Phosphatidylinositol-3′-kinase/AKT Signaling Is Essential in Hepatoblastoma Survival
Wolfgang Hartmann; Jan Küchler; Arend Koch; Nicolaus Friedrichs; Anke Waha; Elmar Endl; Jacqueline Czerwitzki; Dagmar Metzger; Susanne Steiner; Peter Wurst; Ivo Leuschner; Dietrich von Schweinitz; Reinhard Buettner; Torsten Pietsch
Cancer Therapy: Preclinical
PF-00477736 Mediates Checkpoint Kinase 1 Signaling Pathway and Potentiates Docetaxel-Induced Efficacy in Xenografts
Cathy Zhang; Zhengming Yan; Cory L. Painter; Qin Zhang; Enhong Chen; Maria E. Arango; Kyle Kuszpit; Kenneth Zasadny; Max Hallin; Jill Hallin; Anthony Wong; Dana Buckman; Guizhen Sun; Ming Qiu; Kenna Anderes; James G. Christensen
In vivo Antitumor Activity of MEK and Phosphatidylinositol 3-Kinase Inhibitors in Basal-Like Breast Cancer Models
Klaus P. Hoeflich; Carol O'Brien; Zachary Boyd; Guy Cavet; Steve Guerrero; Kenneth Jung; Tom Januario; Heidi Savage; Elizabeth Punnoose; Tom Truong; Wei Zhou; Leanne Berry; Lesley Murray; Lukas Amler; Marcia Belvin; Lori S. Friedman; Mark R. Lackner
Imaging, Diagnosis, Prognosis
SMAD4 Gene Mutations Are Associated with Poor Prognosis in Pancreatic Cancer
Amanda Blackford; Oscar K. Serrano; Christopher L. Wolfgang; Giovanni Parmigiani; Siân Jones; Xiaosong Zhang; D. Williams Parsons; Jimmy Cheng-Ho Lin; Rebecca J. Leary; James R. Eshleman; Michael Goggins; Elizabeth M. Jaffee; Christine A. Iacobuzio-Donahue; Anirban Maitra; John L. Cameron; Kelly Olino; Richard Schulick; Jordan Winter; Joseph M. Herman; Daniel Laheru; Alison P. Klein; Bert Vogelstein; Kenneth W. Kinzler; Victor E. Velculescu; Ralph H. Hruban
Prevalence of TMPRSS2-ERG Fusion Prostate Cancer among Men Undergoing Prostate Biopsy in the United States
Juan-Miguel Mosquera; Rohit Mehra; Meredith M. Regan; Sven Perner; Elizabeth M. Genega; Gerri Bueti; Rajal B. Shah; Sandra Gaston; Scott A. Tomlins; John T. Wei; Michael C. Kearney; Laura A. Johnson; Jeffrey M. Tang; Arul M. Chinnaiyan; Mark A. Rubin; Martin G. Sanda
Imaging Biomarkers Predict Response to Anti-HER2 (ErbB2) Therapy in Preclinical Models of Breast Cancer
Chirayu Shah; Todd W. Miller; Shelby K. Wyatt; Eliot T. McKinley; Maria Graciela Olivares; Violeta Sanchez; Donald D. Nolting; Jason R. Buck; Ping Zhao; M. Sib Ansari; Ronald M. Baldwin; John C. Gore; Rachel Schiff; Carlos L. Arteaga; H. Charles Manning
Cancer Therapy: Clinical
Clinical Relevance of a Pharmacogenetic Approach Using Multiple Candidate Genes to Predict Response and Resistance to Imatinib Therapy in Chronic Myeloid Leukemia
Dong Hwan (Dennis) Kim; Lakshmi Sriharsha; Wei Xu; Suzanne Kamel-Reid; Xiangdong Liu; Katherine Siminovitch; Hans A. Messner; Jeffrey H. Lipton
Partially Matched Related Donor Transplantation Can Achieve Outcomes Comparable with Unrelated Donor Transplantation for Patients with Hematologic Malignancies
Huang Xiao-Jun; Xu Lan-Ping; Liu Kai-Yan; Liu Dai-Hong; Wang Yu; Chen Huan; Chen Yu-Hong; Han Wei; Wang Jing-Zhi; Chen Yao; Zhang Xiao-Hui; Shi Hong-Xia; Wang Feng-Rong; Tang Fei-Fei
Corrections
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale within the United States of Bavencio® (avelumab), a pharmaceutical owned by Merck. If any resulting funds are received, they would not be used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.